Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. The neurometabolic effects of the hallucinogen psilocybin (PSI 0.2 mg/kg), the entactogen 3,4-methylenedioxyethylamphetamine (MDE